How this company measures up on the fundamentals that matter
Journey Medical Corporation, a commercial-stage pharmaceutical company that focuses on the development and commercialization of pharmaceutical products for the treatment of dermatological conditions in the United States. The company's marketed products include Qbrexza, a medicated cloth towelette for the treatment of primary axillary hyperhidrosis; Accutane, an oral isotretinoin drug to treat severe recalcitrant nodular acne; and Amzeeq, a topical formulation of minocycline for the treatment of inflammatory lesions of non-nodular moderate to severe acne vulgaris. It also provides Zilxi, a topical minocycline treatment for inflammatory lesions of rosacea; Emrosi for the treatment of inflammatory lesions of rosacea; Exelderm cream and solution for the treatment of fungal skin infections; and Targadox, an oral doxycycline drug for adjunctive therapy for severe acne, as well as Luxamend, a water-based emulsion formulated to provide a moist healing environment for superficial wounds; minor cuts or scrapes; dermal ulcers; donor sites; first- and second-degree burns, including sunburns; and radiation dermatitis. The company was formerly known as Coronado Dermatology, Inc. Journey Medical Corporation was incorporated in 2014 and is headquartered in Scottsdale, Arizona.
https://journeymedicalcorp.com
Five compliance checks based on AAOIFI standards — all must pass for ethical clearance
Statistical analysis of price behaviour, risk, and market regime — independent of fundamental data
Trading characteristics and market positioning
Balance sheet strength and cash generation — the foundation of long-term value
SEC Form 4 filings — what company insiders are buying and selling
| Date | Insider | Title | Type | Shares | Value |
|---|---|---|---|---|---|
| 2026-04-22 | MARAOUI CLAUDE | Chief Executive Officer | 49,277 | — | |
| 2026-04-22 | BENESCH JOSEPH | Chief Financial Officer | 28,907 | — | |
| 2026-04-22 | ALLOUSH RAMSEY | Chief Operating Officer | 46,863 | — | |
| 2025-08-25 | MARAOUI CLAUDE | Chief Executive Officer | 1,250,000 | $81,250 | |
| 2025-08-05 | ROSENWALD LINDSAY A | Director | 50,000 | — | |
| 2025-08-05 | PEARCE MICHAEL COOPER | Director | 20,000 | — | |
| 2025-08-05 | HERSKOWITZ NEIL | Director | 20,000 | — | |
| 2025-08-05 | TOLEDANO MIRANDA JAYNE | Director | 20,000 | — | |
| 2025-08-05 | SMITH JUSTIN ADAM | Director | 20,000 | — | |
| 2025-06-25 | ROSENWALD LINDSAY A | Director | 7,173 | — |
Data sourced from public filings and market feeds. Not financial advice. Updated: 2026-05-15